Full Press Release Details
Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities.
SGMT
Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities
Key Takeaway: Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+110%
120-day peak, hindsight
Typical move
5.7%
average across 12 past catalysts
Cash runway
~69 mo
Minimal dilution risk
Lead asset
TVB-2640
Phase 2 · Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease